Jaguar Health Inc (JAGX)

Dec 15, 2025

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Central New Jersey News

Dec 15, 2025

Dec 15, 2025

Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada

Dec 15, 2025

Dec 15, 2025

Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus

Dec 15, 2025

Dec 15, 2025

Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com

Dec 15, 2025

Dec 15, 2025

Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan

Dec 15, 2025

Dec 12, 2025

Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks

Dec 12, 2025

Dec 12, 2025

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union

Dec 12, 2025

Dec 11, 2025

Jaguar Health Inc (JAGX) is looking forward to a strong quarter - setenews.com

Dec 11, 2025

Dec 10, 2025

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - Sarasota Herald-Tribune

Dec 10, 2025

Dec 10, 2025

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - The Florida Times-Union

Dec 10, 2025

Dec 10, 2025

FDA extends conditional approval for Jaguar Health’s canine drug By Investing.com - Investing.com Australia

Dec 10, 2025

Dec 10, 2025

FDA extends conditional approval for Jaguar Health’s canine drug - Investing.com

Dec 10, 2025

Dec 09, 2025

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Daytona Beach News-Journal

Dec 09, 2025

Dec 09, 2025

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Bluffton Today

Dec 09, 2025

Dec 08, 2025

Jaguar Health announces promising trial results for crofelemer - MSN

Dec 08, 2025

Dec 08, 2025

Jaguar Health Announces Promising Trial Results for Crofelemer - TipRanks

Dec 08, 2025

Dec 08, 2025

Jaguar Health (NASDAQ: JAGX) clears all special meeting items, notes MVID trial progress - Stock Titan

Dec 08, 2025

Dec 08, 2025

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Livingston Daily

Dec 08, 2025